Propencity score matched results of aspheric and wavefront-guided femtoLASIK evaluation

Session Details

Session Title: LASIK: Flap Morphology and Ablation Profile

Session Date/Time: Monday 09/10/2017 | 08:30-10:20

Paper Time: 09:46

Venue: Room 3.6

First Author: : D.Abelski BELARUS

Co Author(s): :    I. Zabarouski   E. Toropilova                 

Abstract Details

Purpose:

To evaluate results of standard aspheric (SA) and wavefront-guided (WFG) myopic laser-assisted in situ keratomileusis with femtosecond laser-assisted flap formation (femto-LASIK) in completely comparable groups.

Setting:

Belarussian state medical academy of postgaduate education, 10-th Minsk city hospital

Methods:

Data of 88 (55 – SA, 33 – WFG) patients (176 eyes) with myopia chosen from 151 (101 — SA, 50 — WFQ) patients that undergone femto-LASIK (lasers: excimer – VISX STAR® 4 IR; femtosecond – IntraLase® FS 60) by propensity score matching method (PSM) was analyzed. Data included full anamnesis, complaints on vision quality (CVQ) not connected with visual acuity (VA), physical ocular discomfort (POD), filling up NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire) (VFQ), as well as uncorrected VA (UCVA), aberrometry (WaveScan WaveFront® System) before and 6 months after the operation.

Results:

Postoperative refractive result (р=0,93) and UCVA (р=0,67 for UCVA ≥ 1,0, р=0,89 for UCVA 0,55 – 0,8) were almost equal in both groups. Postoperative values of higher-order aberrations (HOA) were substantially lower in Group 2 (p<0,001). Visual life quality improved (р<0,001) in both groups (p=0,24). Percentage of patients with PD increased in Group 1 to 47,3%, in Group 2 to 27,3% (р=0,014) as well as with CVQ: 57,3% in Group 1, 27,3% (р<0,001).

Conclusions:

As a result of PSM analysis SA and WFG femto-LASIK are considered to be commeasurable in refractive outcome, achieved UCVA and BSCVA, visual life quality improvement. WFG femto-LASIK has better statistically significant results in postoperative HOA induction and values, percentage of patients with CVQ and PD.

Financial Disclosure:

NONE